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Hiroki Ienaga1,2 and Kazuhisa Takahashi1Abstract
Background: Tacrolimus is an immunosuppressive drug used to prevent acute rejection following organ
transplantation and to treat autoimmune disease. Tacrolimus is usually prescribed in such situation at a dose of
3.0 mg/day. Pneumocystis pneumonia induced by this dose of tacrolimus has been reported in many cases; however,
we encountered a rare case of Pneumocystis pneumonia induced by low-dose tacrolimus and methylprednisolone.
Case presentation: We herein report the case of an 82-year-old Asian Japanese female with rheumatoid arthritis and
Pneumocystis pneumonia who was being treated with low-dose tacrolimus and low-dose methylprednisolone therapy.
She was diagnosed with rheumatoid arthritis at 52 years of age and was administered oral low-dose methylprednisolone
and salazosulfapyridine. Her condition had been stable under this treatment for 30 years. However, her arthralgia
worsened three months before admission. The salazosulfapyridine was changed to tacrolimus (0.5 mg/day) by her
physician, and her arthralgia almost completely disappeared. She was admitted to our hospital for Pseudomonas
pneumonia, and her symptoms improved almost completely with intravenous ceftazidime therapy. However, on the
14th day of admission, she developed acute respiratory failure due to Pneumocystis pneumonia and died on the
17th day of admission in spite of adequate treatment.
Conclusion: Our report highlights the importance of providing prompt prevention, diagnosis and treatment of
Pneumocystis pneumonia in rheumatoid arthritis patients under tacrolimus and low-dose methylprednisolone therapy.
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Tacrolimus is an immunosuppressive drug often admin-
istered to prevent acute rejection following organ trans-
plantation and to treat autoimmune diseases (e.g.,
rheumatoid arthritis (RA), polymyositis/dermatomyositis
and ulcerative colitis (UC)) and atopic dermatitis. Tacro-
limus is usually administered at a dose of 3.0 mg/day for
these diseases. This dose of tacrolimus can potentially
generate an immunocompromised status, leading to
opportunistic infections (e.g., fungal infection, Pneumo-
cystis pneumonia (PCP) and cytomegalovirus infection).* Correspondence: mtkatou@juntendo.ac.jp
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reproduction in any medium, provided the orOur case of PCP was induced by low-dose tacrolimus
(0.5 mg/day) and low-dose methylprednisolone (mPSL;
4.0 mg/day) administered in a RA patient. We herein re-
port the first case of PCP caused by low-dose tacrolimus.Case presentation
An 82-year-old Asian Japanese female presented to our
hospital with shortness of breath and was admitted for
pneumonia. She had felt ill and had a cough for one
week before admission. Her dyspnea had worsened and
her cough had progressed with the development of
hemosputum three days prior to presentation. Her past
medical history was significant for RA and five prior ad-
missions for pneumonia and bronchiectasis. She had been
diagnosed with RA at 52 years of age and had been admin-
istered oral low-dose mPSL and salazosulfapyridine. Herd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 2 Chest X-ray obtained after the diagnosis of pneumocystis
pneumonia showed areas of ground-glass opacity bilaterally in
almost all lung fields.
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ment for 30 years; however, her arthralgia worsened three
months before admission. The salazosulfapyridine was
changed to low-dose tacrolimus (0.5 mg/day) by her phys-
ician, and her arthralgia almost completely disappeared.
Her initial vital signs were as follows: body temperature,
38.0°C; blood pressure, 132/74 mmHg; heart rate 96
beats/minute; respiratory rate, 22 breaths/minute; and
oxygen saturation (SpO2) on room air, 82%. A physical
examination revealed stridor and bilateral basal expira-
tory wheezes. The laboratory test values were as follows:
white blood cells, 8,400/μL with a left shift; lymphocytes,
740/μL; serum lactate dehydrogenase (LDH), 337 IU/L
(normal, 130–220 IU/L); and serum C-reactive protein
(CRP), 17.58 mg/dL (normal, < 0.3 mg/dL). A chest X-ray
film (Figure 1) showed consolidation in the left middle
lung field. A sputum Gram stain revealed many Gram-
negative organisms, and the sputum culture grew Pseudo-
monas aeruginosa. Treatment with intravenous ceftazidime
(2.0 g/day for nine days) was initiated, and the patient’s
symptoms improved almost completely. On the ninth day
of admission, the CRP level decreased from 17.58 to
4.00 mg/dL. On the 14th day of admission, the patient pre-
sented with severe dyspnea, and a physical examination
was remarkable for an SpO2 of 82% on room air. The ar-
terial blood gas values obtained on 5 L/min of oxygen de-
livered via nasal cannula were as follows: pH: 7.51, PaO2:
52 torr, PaCO2: 46 torr and bicarbonate: 27 mg/dL. A chest
X-ray film (Figure 2) showed areas of ground-glass opacity
(GGO) bilaterally in almost all lung fields. A chest com-
puted tomography (CT) scan (Figure 3A,B) revealed areasFigure 1 Chest X-ray obtained on admission showed consolidation
in the left middle and lower lung fields.
Figure 3 A chest computed tomography scan obtained after
the diagnosis of pneumocystis pneumonia (upper lung field:
3A, lower lung field: 3B) showed areas of nonsegmental
ground-glass opacity and subpleural curvilinear shadows
bilaterally in all lobes.
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with predominance in the upper lobes in both lungs. The
laboratory test values on the 14th day of admission were
as follows: white blood cells, 5270/μL with a left shift;
lymphocytes, 210/μL; serum LDH, 315 IU/L; serum
CRP, 25.8 mg/dL; Krebs von den Lungen-6 (KL-6) level,
457 IU/L (normal, < 500 IU/L); surfactant protein-D
(SP-D), 358 ng/mL (normal, < 110 ng/mL); plasma (1→ 3)
beta-D-glucan level, 716 pg/dL (normal, < 11 pg/mL),
which was high compared with the data obtained before
this admission (17 pg/mL). Assays for latex-agglutination-
Candida antigens and Aspergillus galactomannan antigens
in the serum were both negative. The sputum, urine and
blood cultures grew no organisms. The patient’s sputum
was positive for Pneumocystis jirovecii according to poly-
merase chain reaction (PCR). She was immediately treated
with sulfamethoxazole/trimethoprim (ST) at a dose of
10 mg/kg per day and high-dose mPSL (1 g/day for 3 days)
with empirical antibiotic therapy (ciprofloxacin). However,
her respiratory status rapidly deteriorated and she died on
the 16th day of admission.
Discussion
To our knowledge, this is the first case report of PCP in-
duced by low-dose tacrolimus and steroid therapy for
RA. Tacrolimus is an immunosuppressive drug that was
discovered in Japan. Tacrolimus prevents the dephos-
phorylation of calcineurin and suppresses the production
of inflammatory cytokines (i.e., interleukin (IL)-2, IL-3,
IL-4, interferon-gamma and tumor necrosis factor (TNF)-
alpha from T-cells). It is used to prevent acute rejection
following organ transplantation and to treat autoimmune
disease. In Japan, approximately 12,000 patients with RA
have been treated with tacrolimus since 2005. The efficacy
of tacrolimus has been demonstrated by many researchers,
and the potential toxicity of this drug has also been re-
ported. The major side effects of tacrolimus include renal
dysfunction, interstitial pneumonia, dyspnea, infectious
diseases, hyperglycemia, skin rashes and gastric dysfunc-
tion (e.g., nausea and abdominal pain). Regarding RA pa-
tients with interstitial pneumonitis, tacrolimus has been
reported to be associated with either improvement or
acute exacerbation of interstitial pneumonia. Ando, et al.
reported a case of progressive interstitial pneumonia asso-
ciated with amyopathic dermatomyositis refractory to
cyclosporine that was successfully treated with tacrolimus
[1]. Miwa, et al. reported a case of tacrolimus-induced
lung injury in an RA patient with interstitial pneumonia
[2]. In addition, Koike, et al. reported 27 cases of
tacrolimus-induced lung injury [3]. However, to the best
of our knowledge, even among these cases, there has so
far been no report of lung injury caused by PCP related to
low-dose tacrolimus therapy, while there have only been a
few reports of PCP in RA patients under tacrolimus andlow-dose mPSL therapy. With diseases other than RA,
PCP during tacrolimus therapy has been reported in a pa-
tient after transplantation, and also two patients with UC
[4]. In the setting of organ transplantation, the incidence
of PCP is 4.8 cases per 1,000 person-transplant years [5,6].
No significant risk of PCP was reported in patients under
tacrolimus therapy. However, combined treatment with ta-
crolimus and sirolimus carries a significantly higher risk of
PCP than other types of combination therapy. Among the
UC cases, one patient was medicated with high-dose ta-
crolimus (0.5 mg/kg/day) and mPSL, while the other was
treated with tacrolimus (applied dose: not described) and
6-mercaptopurine. Both patients died from acute respira-
tory failure. Patients with human immunodeficiency virus
(HIV) and autoimmune disease under the administration
of high-dose steroids and immunosuppressants are likely
to develop PCP. The administration of methotrexate or
TNF-alpha inhibitors for autoimmune disease is associ-
ated with a higher risk of PCP than other treatments. In
normal situations, the dose of tacrolimus is 3.0 mg/day;
however, our patient was treated with low-dose tacrolimus
and mPSL. To the best of our knowledge, there are no
previous reports describing PCP induced by such a low
dose of tacrolimus in the literature.
We diagnosed the patient with PCP due to the high
level of beta-D-glucan and positive findings for Pneumo-
cystis jirovecii in the sputum on PCR testing. Tasaka,
et al. suggested that a diagnosis of PCP should be made
based on a beta-D-glucan level above 31.1 mg/dL and
positive findings for Pneumocystis jirovecii in bronchial
alveolar lavage fluid (BALF) on PCR testing [7]. However,
we were unable to perform bronchoscopy in our case due
to the patient’s severe acute progression of respiratory
failure. Therefore, we substituted findings of Pneumo-
cystis jirovecii in the sputum on PCR testing for those in
BALF. Tokuda, et al. reported that RA-related PCP
exhibits both diffuse homogenous GGO with sharp de-
marcation in the interlobular septa and homogenous or
inhomogeneous GGO with sharp demarcation in the
intralobular septa on chest CT [8]. The chest CT findings
observed in our case revealed non-homogenous GGO
without interlobular septal boundaries in accordance with
RA-related PCP. We administered steroid pulse therapy
with ST because the rapid progression of respiratory fail-
ure did not allow us to sufficiently examine and differenti-
ate the etiology of the disease in this case. Our patient was
diagnosed with and treated for Pseudomonas pneumonia
before diagnose of PCP was made. John, et al. reported
that blood CD4+ lymphocyte counts in PCP patients with
HIV were lower than 200/μL [9]. Enomoto, et al. reported
that average lymphocyte counts in 17 RA patients compli-
cated with PCP were 890/μL at the time of PCP diagnosis
[10]. In our case, blood lymphocyte count was 1700/μL
at the time of diagnosis of Pseudomonas pneumonia,
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The decreased lymphocyte count was considered to be
due to the Pseudomonas pneumonia. Therefore, it was
considered that some of the changes that occur in the im-
mune response due to the effects of Pseudomonas pneu-
monia have the potential to trigger PCP. RA-related PCP
has a higher mortality rate than HIV-related PCP [11]. It
is assumed that providing diagnosis and treatment in the
early stage of development of PCP achieves prognostic im-
provements in RA patients. Our patient rapidly developed
respiratory failure following diagnosis and treatment.
Conclusions
In conclusion, we herein reported the first case of PCP
induced by low-dose tacrolimus and steroid treatment
for RA. Clinicians should be careful to watch for the devel-
opment of PCP following the administration of tacrolimus
even in small doses in elderly patients and patients with a
history of lung disease.
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